TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The Company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The Company also developed the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform.

Company Growth (employees)
Morrisville, US
Size (employees)
103 (est)
TransEnterix was founded in 2006 and is headquartered in Morrisville, US

Key People/Management at TransEnterix

Todd M. Pope

Todd M. Pope

President & CEO

TransEnterix Office Locations

TransEnterix has offices in Morrisville and Trezzano Rosa
Morrisville, US (HQ)
300 635 Davis Dr
Trezzano Rosa, IT
40 Via Firenze

TransEnterix Financials and Metrics

TransEnterix Financials

TransEnterix's revenue was reported to be $1.5 m in FY, 2016

Revenue (Q2, 2017)

1.6 m

Gross profit (Q2, 2017)

612 k

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(14.7 m)

EBIT (Q2, 2017)

(14.8 m)

Market capitalization (13-Nov-2017)

477 m

Cash (30-Jun-2017)

29.7 m
TransEnterix's current market capitalization is $477 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


1.4 m401 k1.5 m

Revenue growth, %


Cost of goods sold

4.8 m1.1 m1.1 m

Gross profit

(3.4 m)(694 k)450 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


362 k93 k113 k61 k93 k113 k61 k1.5 m1.9 m1.6 m

Cost of goods sold

2.1 m220 k238 k202 k220 k238 k202 k1 m1.3 m972 k

Gross profit

(1.7 m)(127 k)(125 k)(141 k)(127 k)(125 k)(141 k)435 k612 k612 k

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


10 m34.8 m38.4 m24.2 m

Accounts Receivable

188 k133 k76 k621 k


3.9 m7.9 m

Current Assets

17.8 m35.7 m49.1 m38 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


23.8 m4.2 m52.6 m44.3 m28.4 m71.1 m52.9 m53.5 m64.6 m42.5 m13.1 m29.7 m

Accounts Receivable

294 k52 k96 k38 k53 k8 k78 k79 k77 k616 k1.8 m1.7 m


766 k651 k438 k267 k3.4 m3.6 m4.2 m2.3 m8.3 m9.5 m

Current Assets

27.1 m10.2 m53.7 m45.5 m29.1 m71.7 m61.9 m64.3 m76 m53.5 m28.8 m48.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(28.4 m)(37.7 m)(46.9 m)(120 m)

Depreciation and Amortization

1.5 m1.3 m2.2 m7 m

Accounts Receivable

402 k55 k133 k(1 m)


731 k701 k(1.9 m)(6.6 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(20.3 m)(7.5 m)(18.1 m)(29.6 m)(10.1 m)(19.5 m)(33.4 m)(12.9 m)(93 m)(106 m)(15.4 m)(30.1 m)

Depreciation and Amortization

1.1 m286 k594 k936 k390 k768 k1.4 m2.4 m4.7 m6.8 m2.2 m4.5 m

Accounts Receivable

251 k136 k92 k150 k80 k125 k133 k80 k125 k(809 k)(753 k)(487 k)


667 k50 k263 k434 k50 k263 k(250 k)(1.7 m)(4 m)(1.9 m)(320 k)(862 k)
Y, 2017

Financial Leverage

1.5 x
Show all financial metrics

TransEnterix Operating Metrics

TransEnterix's Patent Applications was reported to be 40 in FY, 2016
FY, 2016

Patent Applications


Patents Issued

Show all operating metrics

TransEnterix Market Value History

TransEnterix's Web-traffic and Trends

TransEnterix Online and Social Media Presence

TransEnterix News and Updates

Surgical Robots Market Perceives Enormous Accruals with a Staggering double digit CAGR of~ 22.75% by 2023; Asserts MRFR

Global surgical robots market research report, by Control Mechanism (Direct Telemanipulator and Computer Control), by Robotic Surgery Approach (Supervisor-Controlled Robotic Surgical System, Shared Control Robotic Surgical Systems, Telesurgery Systems, Robotic Radiosurgery Systems), by Application (…

TransEnterix Company Life and Culture

You may also be interested in